NCT01557855

Brief Summary

The objective of this study is to collect data on the commercial use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood test to evaluate the clinical referral patterns of Primary Care Physicians after receipt of their patients' Corus Score, and to better understand patient management patterns for clinicians ordering the test.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
342

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2012

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 20, 2012

Completed
12 days until next milestone

Study Start

First participant enrolled

April 1, 2012

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

January 31, 2019

Status Verified

January 1, 2019

Enrollment Period

11 months

First QC Date

March 16, 2012

Last Update Submit

January 29, 2019

Conditions

Keywords

Corus CADASGESAge/Sex/Gene Expression ScoreGene ExpressionGESCADCVDCHDPrecision MedicineClinical UtilityRegistryCoronary Artery DiseaseCoronary Heart DiseaseCardiovascular DiseaseAngina PectorisChest PainRegistry IRegistry-I

Outcome Measures

Primary Outcomes (1)

  • Rate of referral vs. Corus CAD (ASGES) score as continuous variables

    Composite endpoint consisting of referrals to a cardiologist, to cardiac stress/CTA and/or to invasive cardiac catheterization occurring between Day 0 and Day 30 + 15 days.

    30 Days

Secondary Outcomes (1)

  • Rate of referral difference between low Corus CAD or ASGES (</=15) and non-low ASGES (>15) scores.

    30 Day

Interventions

Corus CAD (ASGES)DIAGNOSTIC_TEST

Age/Sex/Gene Expression Score - ASGES

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects will be enrolled at multiple qualified participating study centers that have incorporated Corus CAD (ASGES) for the diagnosis of obstructive CAD into their routine practice.

You may qualify if:

  • Patients with symptoms suggestive of CAD, including typical or atypical angina or angina equivalent
  • The patient has signed the appropriate Institutional Review Board approved Informed Consent Form

You may not qualify if:

  • History of myocardial infarction
  • Current MI or acute coronary syndrome
  • Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms
  • Any previous coronary Revascularization
  • Any individuals with:
  • Diabetes
  • Suspected unstable angina
  • Systemic infections
  • Systemic inflammatory conditions
  • Any individuals currently taking:
  • Steroids
  • Immunosuppressive agents
  • Chemotherapeutic agents
  • Recipient of any organ transplant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Arizona Sun Family Medicine

Gilbert, Arizona, 85296, United States

Location

Fiel Family Medicine

Tempe, Arizona, 85283, United States

Location

Town Lake Internal Medicine

Woodstock, Georgia, 30189, United States

Location

Maringouin Medical Center

Maringouin, Louisiana, 70757, United States

Location

The Bonin Clinic

Zachary, Louisiana, 70791, United States

Location

Triangle Primary Care

Wake Forest, North Carolina, 27587, United States

Location

Comprehensive Physicians Associates

Youngstown, Ohio, 44505, United States

Location

Related Publications (2)

  • Ladapo JA, Lyons H, Yau M, Rich P, Newton D, Bruce-Mensah K, Johnson A, Zhou Y, Stemkowski S, Monane M. Enhanced assessment of chest pain and related symptoms in the primary care setting through the use of a novel personalized medicine genomic test: results from a prospective registry study. Am J Med Qual. 2015 Jul-Aug;30(4):345-52. doi: 10.1177/1062860614532517. Epub 2014 May 5.

  • Ladapo JA, Herman L, Weiner BH, Rhees B, Castle L, Monane M, McPherson JA. Use of a blood test incorporating age, sex, and gene expression influences medical decision-making in the evaluation of women presenting with symptoms suggestive of obstructive coronary artery disease: summary results from two ambulatory care studies in primary care. Menopause. 2015 Nov;22(11):1224-30. doi: 10.1097/GME.0000000000000443.

MeSH Terms

Conditions

Coronary Artery DiseaseAngina PectorisChest PainCardiovascular DiseasesCoronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Michael Zapien, MS

    CardioDx

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 16, 2012

First Posted

March 20, 2012

Study Start

April 1, 2012

Primary Completion

March 1, 2013

Study Completion

May 1, 2013

Last Updated

January 31, 2019

Record last verified: 2019-01

Locations